Wolfe Research Initiates Coverage on Repligen (NASDAQ:RGEN)

Stock analysts at Wolfe Research started coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Thursday, Marketbeat.com reports. The firm set a “peer perform” rating on the biotechnology company’s stock.

Several other equities analysts have also commented on the stock. Wells Fargo & Company started coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. UBS Group dropped their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Finally, JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Down 12.4 %

RGEN stock opened at $124.73 on Thursday. The company’s 50 day moving average price is $141.54 and its 200 day moving average price is $144.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The firm has a market capitalization of $6.99 billion, a price-to-earnings ratio of -337.10, a PEG ratio of 4.36 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.23 earnings per share. On average, equities research analysts anticipate that Repligen will post 1.44 EPS for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Repligen

Institutional investors have recently made changes to their positions in the stock. Andra AP fonden purchased a new stake in shares of Repligen during the 2nd quarter worth $25,000. Lazard Asset Management LLC boosted its position in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV purchased a new stake in shares of Repligen in the 3rd quarter worth about $37,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.